Evidence map›Paper›PMID 40533425›Full record

ReviewESC heart failure2025

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review.

Johann Bauersachs, Eri Toda Kato, Janani Rangaswami

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07719621 (Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07719621 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D

TypeobservationalSponsorAeterna Medical Solutions SLRan2026 to 2026Enrolled50,000ConditionsCKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Johann BauersachsDepartment of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0002-9341-117X
Eri Toda KatoDepartment of Cardiovascular Medicine and Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Janani RangaswamiGeorge Washington University, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal activation and fibrosis. Early diagnosis and intervention are important to slow CKD progression and reduce HF events. Shared therapeutic targets for CKD and HF include the renin-angiotensin system (RAS), sodium-glucose cotransporter 2 (SGLT2), mineralocorticoid receptor (MR) and glucagon-like peptide-1 (GLP-1) receptor. For the management of CKD, current treatment guidelines recommend the use of RAS inhibitors, SGLT2 inhibitors, the nonsteroidal MR antagonist finerenone and GLP-1 receptor agonists. Challenges in the management of patients with CKD and HF include the presence of other comorbidities, leading to polypharmacy. This review highlights gaps and opportunities for improving the management of patients with CKD and chronic HF.

Indexed as

Disease ManagementHeart FailureRenal Insufficiency, ChronicGlobal HealthHumansMineralocorticoid Receptor AntagonistsRenin-Angiotensin SystemSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsChronic heart failureChronic kidney diseaseGlucagon‐like peptide‐1 receptor agonistMineralocorticoid receptor antagonistPathogenesisSodium‐glucose cotransporter 2 inhibitor

Identifiers

PMID40533425
PMCPMC12450771

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.